...
首页> 外文期刊>BMC Cancer >Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast
【24h】

Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast

机译:Tiam1过表达在乳腺浸润性导管癌中的临床病理意义

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background T-lymphoma invasion and metastasis-inducing protein 1 (Tiam1) has been implicated in tumor occurrence and progression. Recent studies have shown that high expression levels of Tiam1 protein appear to be associated with the progression of numerous human tumors. This study attempted to explore the role of Tiam1 protein in tumor progression and the prognostic evaluation of breast cancer. Methods The localization of the Tiam1 protein was determined in the MDA-MB-231 breast cancer cell line using immunofluorescence (IF) staining. In addition, a total of 283 breast tissue samples, including 153 breast cancer tissues, 67 ductal carcinoma in situ (DCIS) and 63 adjacent non-tumor breast tissues, were analyzed by immunohistochemical (IHC) staining of the Tiam1 protein. The correlation between Tiam1 expression and clinicopathological characteristics was evaluated by Chi-square test and Fisher’s exact tests. Disease-free survival (DFS) and 10-year overall survival (OS) rates were calculated by the Kaplan-Meier method. Additionally, univariate and multivariate analyses were performed by the Cox proportional hazards regression models. Results Tiam1 protein showed a mainly cytoplasmic staining pattern in breast cancer cells; however, nuclear staining was also observed. Tiam1 protein expression was significantly higher in breast cancers (42.5?%, 65/153) and DCIS (40.3?%, 27/67) than in adjacent non-tumor tissues (12.7?%, 8/63). In addition, Tiam1 associated with tumor stage and Ki-67 expression, but negatively correlated with receptor tyrosine-protein kinase erbB-2 (Her2) expression. Moreover, survival analyses showed that DFS and 10-year OS rates were significantly lower in breast cancer patients with high Tiam1 expression than those with low Tiam1 expression. Univariate analysis suggested that molecular types, clinical stage, Her2 expression levels and Tiam1 expression levels were also significantly associated with DFS and 10-year OS rates of breast cancer patients. Furthermore, multivariate analysis suggested that Tiam1 expression is a significant independent prognostic factor along with tumor stage in patients with breast cancer. Conclusions Tiam1 expression is frequently up-regulated in breast cancer. Tiam1 expression correlated with clinicopathological parameters, suggesting that it may be a useful prognostic biomarker and potential therapeutic target for patients with breast cancer.
机译:背景T淋巴瘤侵袭和转移诱导蛋白1(Tiam1)与肿瘤的发生和发展有关。最近的研究表明,Tiam1蛋白的高表达水平似乎与许多人类肿瘤的进展有关。这项研究试图探讨Tiam1蛋白在肿瘤进展和乳腺癌预后评估中的作用。方法采用免疫荧光(IF)染色法检测MDA-MB-231乳腺癌细胞中Tiam1蛋白的定位。此外,通过Tiam1蛋白的免疫组织化学(IHC)染色分析了总共283个乳房组织样本,包括153个乳腺癌组织,67个原位导管癌(DCIS)和63个相邻的非肿瘤乳房组织。通过卡方检验和Fisher精确检验评估了Tiam1表达与临床病理特征之间的相关性。通过Kaplan-Meier方法计算无病生存期(DFS)和10年总生存期(OS)。此外,通过Cox比例风险回归模型进行了单变量和多变量分析。结果Tiam1蛋白在乳腺癌细胞中主要表现为胞浆染色。但是,也观察到了核染色。 Tiam1蛋白的表达在乳腺癌(42.5%,65/153)和DCIS(40.3%,27/67)中显着高于相邻的非肿瘤组织(12.7%,8/63)。此外,Tiam1与肿瘤分期和Ki-67表达相关,但与受体酪氨酸蛋白激酶erbB-2(Her2)表达负相关。此外,生存分析表明,Tiam1高表达的乳腺癌患者的DFS和10年OS率显着低于Tiam1低表达的乳腺癌患者。单因素分析表明,分子类型,临床分期,Her2表达水平和Tiam1表达水平也与乳腺癌患者的DFS和10年OS率显着相关。此外,多变量分析表明,Tiam1表达与乳腺癌患者的肿瘤分期一起是重要的独立预后因素。结论Tiam1表达在乳腺癌中经常被上调。 Tiam1表达与临床病理参数相关,表明它可能是乳腺癌患者的有用的预后生物标志物和潜在的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号